Post-Approval Change Submission Vehicle Matrix

Document type	Matrix
Topic area	Regulatory CMC
Level	Advanced
Updated	September 2026

This is a ready-to-use matrix for classifying a post-approval manufacturing, facility, or control change against the correct FDA and EU submission vehicle before the change reaches the floor. Attach it to the relevant change control record; this is the document a pre-approval or post-approval inspection is checking for when it asks whether a floor change was mapped back to a filing obligation. Replace every <<FILL: ...>> placeholder with your own specifics. A worked filled specimen follows. Verify each cited reference against the current source before you rely on it.

Document control header

Field	Entry
Document title	Post-Approval Change Classification for `<<FILL: change description>>`
Document number	`<<FILL: e.g. MTX-PAC-018>>`
Version	`<<FILL>>`
Linked change control number	`<<FILL>>`
Application(s) affected	`<<FILL: BLA/NDA number(s), market(s)>>`
Document owner	`<<FILL: e.g. Regulatory Affairs Lead>>`

1. Purpose

This matrix classifies a proposed change by its potential effect on product identity, strength, quality, purity, or potency, and maps that classification to the submission vehicle required in every market where the product is approved, so the change is filed correctly before it is implemented on the floor, not reconciled against the filing after the fact.

2. Scope

Dimension	Decision
Change under assessment	`<<FILL>>`
Markets / applications in scope	`<<FILL: e.g. US BLA, EU centralized MA>>`
Filed content potentially affected	`<<FILL: e.g. S.2.5 batch count, P.3.5 process description, a specification>>`
Out of scope	`<<FILL: e.g. labeling-only changes, covered under a separate procedure>>`

3. Responsibilities

Role	Responsibility
Regulatory affairs lead	Owns the classification decision per market and the submission timing
Change control owner	Ensures this matrix is triggered before the change is implemented
CMC / validation science lead	Supplies the technical basis for the potential-effect determination
Quality Assurance	Confirms the change is not implemented ahead of the classification’s required timing

4. Potential-effect classification

Question	Answer
Does the change fall outside the range or scope the original validation, comparability, or process characterization data actually support?	`<<FILL>>`
Could the change plausibly affect identity, strength, quality, purity, or potency as they relate to safety or effectiveness?	`<<FILL>>`
Is there a specific FDA or EU guidance document naming this change type at a stated classification?	`<<FILL: cite if yes>>`
Overall potential effect	`<<FILL: Major / Moderate / Minor>>`

5. Submission vehicle by market

Market	Vehicle	Basis	Implementation timing
US (FDA, 21 CFR 314.70 / 601.12)	`<<FILL: Prior Approval Supplement / CBE-30 / CBE-0 / Annual Report>>`	`<<FILL>>`	`<<FILL: before approval / after 30-day window / immediately, narrow cases / with next annual report>>`
EU (centralized or national, current EC variations guidelines)	`<<FILL: Type II / Type IB / Type IA>>`	`<<FILL>>`	`<<FILL: before approval / after tacit-approval wait / after implementation, do-and-tell>>`
`<<FILL: additional market, if applicable>>`	`<<FILL>>`	`<<FILL>>`	`<<FILL>>`

6. Conclusion and required action

Field	Entry
Classification confirmed by Regulatory Affairs	`<<FILL: Yes/No>>`
Submission(s) required before the change proceeds	`<<FILL: list by market>>`
Owner and target filing date for each submission	`<<FILL>>`
Can the change proceed on the floor before filing/approval is complete?	`<<FILL: Yes/No, with justification per market>>`

7. References

21 CFR 314.70, Supplements and other changes to an approved NDA. 21 CFR 601.12, Changes to an approved application (BLA). Regulation (EU) 2024/1701, amending Regulation (EC) No 1234/2008 on variations to marketing authorisations (applicable from 1 January 2025), and the current EC variations classification guidelines (applicable from 15 January 2026, superseding the 2013 version).

Confirm the current version and status of each reference before issue; the EU variations framework changed materially in 2025-2026 and an internal classification guide written before that update is superseded.

8. Revision history

Version	Date	Author	Summary of change
`<<FILL: 1.0>>`	`<<FILL>>`	`<<FILL>>`	Initial issue.

9. Approvals

Role	Name	Signature	Date
Author (Regulatory Affairs)	`<<FILL>>`
Reviewer (CMC / Validation)	`<<FILL>>`
Approver (QA)	`<<FILL>>`

Filled specimen

Extract for an example change control widening a drug substance chromatography step’s validated resin lifetime claim, from 50 cycles to 75 cycles, supported by new bridging data. Company and product are illustrative.

Potential-effect classification: the change moves the process outside the range explicitly validated in the original PPQ and characterization studies (up to 50 cycles); resin performance late in an extended lifetime can plausibly affect purity through leachables or reduced binding capacity, so the potential effect is assessed as moderate, supported by the new bridging data rather than major, since the resin chemistry, column, and process parameters are otherwise unchanged.

Market	Vehicle	Basis	Implementation timing
US (FDA, 21 CFR 601.12)	CBE-30	Moderate potential effect; bridging data supports the extended range without a change to the process itself	After the 30-day FDA review window, absent an FDA hold
EU (centralized, current EC variations guidelines)	Type IB	Minor variation under the current classification guideline for an in-process control range widening supported by data	After the standard tacit-approval wait period

Conclusion: classification confirmed by Regulatory Affairs. Submissions required: US CBE-30 and EU Type IB, both referencing the same bridging data package. The change cannot proceed to commercial manufacture in either market until the respective submission’s implementation timing has been satisfied; the change control record remains open in both markets independently, since one market clearing its wait period does not clear the other.

Common inspection findings this matrix prevents

A change implemented on the floor before its submission vehicle’s required timing was satisfied in any one of the product’s markets.
A change classified once and assumed to transfer identically to every market, when the actual potential-effect basis differs by market’s approved content.
An EU variation classified against a superseded internal guide, after the framework changed in 2025-2026.
A change control closed with no documented linkage to the submission(s) it actually required.

How to adapt this matrix

List every market and application the change could affect in section 2; a change classified for one market only is a common way a second market’s obligation gets missed.
Base the potential-effect classification in section 4 on the actual validation and comparability data, not an assumption that a small-sounding change is automatically minor.
Confirm the current EU variations guideline edition before classifying a Type IA/IB/II tier; the framework was updated in 2025-2026.
Do not allow floor implementation to proceed in any market ahead of that market’s required submission timing in section 6.